您当前所在的位置:首页 > 产品中心 > 产品信息
Flupirtine maleate_分子结构_CAS_75507-68-5)
点击图片或这里关闭

Flupirtine maleate

产品号 S1334 公司名称 Selleck Chemicals
CAS号 75507-68-5 公司网站 http://www.selleckchem.com
分子式 C19H21FN4O6 电 话 (877) 796-6397
分子量 420.3916432 传 真 (832) 582-8590
纯 度 电子邮件 sales@selleckchem.com
保 存 -20°C Chembase数据库ID: 72625

产品价格信息

请登录

产品别名

标题
Flupirtine maleate
IUPAC标准名
(2E)-but-2-enedioic acid ethyl N-(2-amino-6-{[(4-fluorophenyl)methyl]amino}pyridin-3-yl)carbamate
IUPAC传统名
flupirtine; fumaric acid
别名
Katadolon

产品登记号

CAS号 75507-68-5

产品性质

作用靶点 Antimetabolites
成盐信息 Maleate
保存条件 -20°C

产品详细信息

详细说明 (English)
Research Area
Description Cancer
Protocol
Cell Assay [4]
Cell Lines PC12 cell
Concentrations 1 or 5 μg/mL
Incubation Time 72 hours
Methods

For measurement of viability and generation of reactive oxygen intermediates, PC12 cells are seeded in 24- or 96-well plates coated with poly-L-lysine at 105 cells/mL. Drugs are dissolved in PBS (pH 7.4), or ethanol and filtered sterile. At the end of each experiment cells are trypsinized and pelleted together with cells of the culture supernatant. After staining for 10 min with 0.2% Trypan blue solution live (unstained) and dead (Trypan blue positive) cells are counted in a hemocytometer chamber. In addition, cellular viability is evaluated by the reduction of MTT to formazan. After 2 hours incubation with MTT (0.5 mg/ml) at 37 °C, cells are lysed in DMSO. Extinction at 570 nm is determined on a plate photometer. For staining of surviving adherent cells, plates are incubated for 10 min with 0.5% crystalviolet dissolved in 20% methanol. Plates are rinsed with water and stained cells are lysed in 50% ethanol, 0.1 M sodiumcitrate before determining extinction at 550 nm.

Animal Study [7]
Animal Models male Wistar rats with cerebral ischemia induced by four-vessel-occlusion
Formulation sterile 0.9% sodium chloride solution
Doses 5 mg/kg
Administration Intraperitoneal injection either 20 min before and 50 min after occlusion or directly and 70 min after occlusion
References
[1] Perovic S, et al. Eur J Pharmacol, 1994, 288(1), 27-33.
[2] Rupalla K, et al. Eur J Pharmacol, 1995, 294(2-3), 469-473
[3] Müller WE, et al. J Neurochem, 1997, 68(6), 2371-2377.
[4] Seyfried J, et al. Eur J Pharmacol, 2000, 400(2-3):155-166.
[5] Dörr J, et al. J Neuroimmunol, 2005, 167(1-2), 204-209.
[6] Kornhuber J, et al. J Neural Transm, 1999, 106(9-10), 857-867.
[7] Block F, et al. Brain Res, 1997, 754(1-2), 279-284.
[8] Bleyer H, et al. Eur J Pharmacol, 1988, 151(2), 259-265.
[9] Nickel B, et al. Arzneimittelforschung, 1990, 40(8), 909-911.